Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

427
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
427
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

470
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
470

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Clinically Relevant Threshold of Impaired Contrast Sensitivity Among Older US Adults.

JAMA ophthalmology·2026
Same author

Silicon Nanoneedle Patches for Painless, Sustained Treatment of Macular Degeneration.

ACS biomaterials science & engineering·2026
Same author

Improving Operating Room Access and Utilization at an Academic Ophthalmology Department.

Ophthalmic surgery, lasers & imaging retina·2025
Same author

Photo-Mediated Ultrasound Therapy (PUT) for the Treatment of Deep Cutaneous Vasculature.

IEEE open journal of ultrasonics, ferroelectrics, and frequency control·2025
Same author

Leveraging retrieval-augmented large language models for patient education in ophthalmology.

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie·2025
Same author

Novel Handheld Device for Remote Monitoring of Dry Macular Degeneration and Patient Usability Assessment.

Diagnostics (Basel, Switzerland)·2025

Related Experiment Video

Updated: Jun 21, 2025

Quantification of Diabetes-induced Adherent Leukocytes in Retinal Vasculature
06:09

Quantification of Diabetes-induced Adherent Leukocytes in Retinal Vasculature

Published on: January 24, 2025

219

Adjunct Nondamaging Focal Laser Reduces Intravitreal Injection Burden in Diabetic Macular Edema.

Lyna Azzouz1,2, Asad Durrani1, Yunshu Zhou1

  • 1Department of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor, MI 48105, USA.

Photonics
|July 15, 2024
PubMed
Summary

Nondamaging focal laser therapy significantly reduced anti-vascular endothelial growth factor (anti-VEGF) injections for diabetic macular edema (DME) patients. This treatment lowered injection burden without negatively impacting visual acuity or macular thickness.

Keywords:
Endpoint Management laseranti-vascular endothelial growth factordiabetic macular edemadiabetic retinopathyfocal laser

More Related Videos

Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology
06:19

Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology

Published on: May 31, 2024

770
Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases
11:20

Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases

Published on: June 14, 2021

3.7K

Related Experiment Videos

Last Updated: Jun 21, 2025

Quantification of Diabetes-induced Adherent Leukocytes in Retinal Vasculature
06:09

Quantification of Diabetes-induced Adherent Leukocytes in Retinal Vasculature

Published on: January 24, 2025

219
Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology
06:19

Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology

Published on: May 31, 2024

770
Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases
11:20

Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases

Published on: June 14, 2021

3.7K

Area of Science:

  • Ophthalmology
  • Retinal Diseases
  • Medical Technology

Background:

  • Diabetic macular edema (DME) is a leading cause of vision loss.
  • Anti-vascular endothelial growth factor (anti-VEGF) injections are a common treatment for DME.
  • Managing DME requires frequent injections, posing a burden on patients and healthcare systems.

Purpose of the Study:

  • To evaluate the impact of nondamaging focal laser therapy on anti-VEGF injection frequency.
  • To assess changes in visual acuity (VA) and macular thickness post-laser treatment.
  • To determine if focal laser therapy can reduce the treatment burden for DME patients.

Main Methods:

  • Retrospective analysis of 18 eyes from 14 DME patients.
  • Treatment involved a single session of PASCAL 532 nm Synthesis Photocoagulator.
  • Collected data on VA, imaging, laser parameters, and anti-VEGF injections six months before and after treatment.

Main Results:

  • Mean intravitreal injections decreased from 3.39 before to 2.33 after laser treatment (p=0.02).
  • No significant changes were observed in visual acuity (logMAR 0.38 vs. 0.35, p=0.34).
  • Optical Coherence Tomography (OCT) showed no significant difference in central macular thickness (311 μm vs. 301 μm, p=0.64).

Conclusions:

  • Adjunct focal laser therapy significantly reduces the need for anti-VEGF injections in DME patients.
  • This therapy maintains visual acuity and macular thickness.
  • Nondamaging focal laser offers a potential method to decrease the injection burden for DME management.